Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 When and how to treat chronic lymphocytic leukemia.

Literature DB >> 11114321

When and how to treat chronic lymphocytic leukemia.

G Dighiero, J L Binet.

Abstract

Entities: Disease

Mesh：

Substances：

Year: 2000 PMID： 11114321 DOI： 10.1056/NEJM200012143432410

Source DB: PubMed Journal: N Engl J Med ISSN： 0028-4793 Impact factor: 91.245

Keyword Cloud
Cited

× No keyword cloud information.

24 in total

1. miR-181b is a biomarker of disease progression in chronic lymphocytic leukemia.

Authors: Rosa Visone; Angelo Veronese; Laura Z Rassenti; Veronica Balatti; Dennis K Pearl; Mario Acunzo; Stefano Volinia; Cristian Taccioli; Thomas J Kipps; Carlo M Croce
Journal: Blood Date: 2011-06-02 Impact factor: 22.113

Review 2. Current and developing chemotherapy for CLL.

Authors: Emili Montserrat
Journal: Med Oncol Date: 2002 Impact factor: 3.064

Review 3. Eradication of minimal residual disease in chronic lymphocytic leukemia.

Authors: Carmen Diana Schweighofer; Michael Hallek; Clemens-Martin Wendtner
Journal: Curr Hematol Malig Rep Date: 2008-01 Impact factor: 3.952

4. Dendritic cells from chronic lymphocytic leukemia patients are normal regardless of Ig V gene mutation status.

Authors: Davorka Messmer; Gloria Telusma; Tarun Wasil; Bradley T Messmer; Steven Allen; Kanti R Rai; Nicholas Chiorazzi
Journal: Mol Med Date: 2004 Jul-Dec Impact factor: 6.354

Review 5. Therapy of chronic lymphocytic leukaemia with purine nucleoside analogues: facts and controversies.

Authors: Tadeusz Robak
Journal: Drugs Aging Date: 2005 Impact factor: 3.923

6. Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia.

Authors: Laura Z Rassenti; Sonia Jain; Michael J Keating; William G Wierda; Michael R Grever; John C Byrd; Neil E Kay; Jennifer R Brown; John G Gribben; Donna S Neuberg; Feng He; Andrew W Greaves; Kanti R Rai; Thomas J Kipps
Journal: Blood Date: 2008-06-24 Impact factor: 22.113

When and how to treat chronic lymphocytic leukemia.

1. miR-181b is a biomarker of disease progression in chronic lymphocytic leukemia.

Review 2. Current and developing chemotherapy for CLL.

Review 3. Eradication of minimal residual disease in chronic lymphocytic leukemia.

4. Dendritic cells from chronic lymphocytic leukemia patients are normal regardless of Ig V gene mutation status.

Review 5. Therapy of chronic lymphocytic leukaemia with purine nucleoside analogues: facts and controversies.

6. Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia.

7. CXCL12-induced chemotaxis is impaired in T cells from patients with ZAP-70-negative chronic lymphocytic leukemia.

8. Unusual case of unilateral conductive hearing loss: chronic lymphocytic leukaemia.

Review 9. Advances in the understanding of biology and prognosis in chronic lymphocytic leukemia.

10. First-line treatment of chronic lymphocytic leukemia: role of alemtuzumab.